ABL1 myristoyl pocket

Trials

150 participants · First posted Sep 5, 2025

Completed

NCT02589808

Preoperative Pocket Echocardiography Trial

76 participants · First posted Oct 28, 2015

Recruiting

NCT06458062

Pocket Colposcopy Using CARE Algorithm

1,079 participants · First posted Jun 13, 2024

Drugs

View all 73 →

Small Molecule

Experimental

Myristoyl-Coa

C₃₅H₆₂N₇O₁₇P₃S

Small Molecule

Approved

Chlorhexidine(Betasept, Hibiclens, Instillagel, Nupro Chlorhexidine, Oris, Oro-Clense, Paroex, Perichlor, Peridex, Periochip, Periogard, Prevora, X-pur)

Manufacturer: Xttrium laboratories inc, Sage products inc +20 more

Conditions: Aphthous ulcer, Catarrh of the throat +51 more

C₂₂H₃₀Cl₂N₁₀

Small Molecule

Approved

Asciminib(Scemblix)

Conditions: Chronic Phase Chronic Myeloid Leukemia

C₂₀H₁₈ClF₂N₅O₃

Organizations

View all 9 →

Pocket Naloxone Corp.

United States

Elutia

Ably Medical AS

Norway

News

View all 391 →

last year

Novartis Receives CDSCO Approval for Phase IIIb Trial of Asciminib in Chronic Myeloid Leukemia

6 months ago

FDA Accepts PBPK Modeling to Replace Ten Clinical Trials for CML Drug Asciminib

last year

Trials

Identification of BCR::ABL1 Mutations by Digital PCR in CML

Preoperative Pocket Echocardiography Trial

Pocket Colposcopy Using CARE Algorithm

Drugs

Myristoyl-Coa

Chlorhexidine(Betasept, Hibiclens, Instillagel, Nupro Chlorhexidine, Oris, Oro-Clense, Paroex, Perichlor, Peridex, Periochip, Periogard, Prevora, X-pur)

Asciminib(Scemblix)

Organizations

Pocket Naloxone Corp.

Elutia

Ably Medical AS

News

Novartis Receives CDSCO Approval for Phase IIIb Trial of Asciminib in Chronic Myeloid Leukemia

FDA Accepts PBPK Modeling to Replace Ten Clinical Trials for CML Drug Asciminib

FDA Approves Scemblix (asciminib) for First-Line Treatment of Chronic Myelogenous Leukemia